Addex Therapeutics Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.09%

Addex Therapeutics Ltd (ADXN) has an Asset Resilience Ratio of 0.09% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Addex Therapeutics Ltd carry for a breakdown of total debt and financial obligations.

Liquid Assets

CHF6.86K

≈ $8.67K USD Cash + Short-term Investments

Total Assets

CHF7.33 Million

≈ $9.27 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how Addex Therapeutics Ltd's Asset Resilience Ratio has changed over time. See ADXN book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Addex Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Addex Therapeutics Ltd.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF0.00	0%
Short-term Investments	CHF6.86K	0.09%
Total Liquid Assets	CHF6.86K	0.09%

Asset Resilience Insights

Limited Liquidity: Addex Therapeutics Ltd maintains only 0.09% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Addex Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Addex Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	25.67%
Tubize-Fin BR:TUB	Biotechnology	0.05%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
Dashenlin Pharm Grp Co Ltd SHG:603233	Biotechnology	0.02%
Staidson Beijing Biopharma SHE:300204	Biotechnology	7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	41.25%
Ardelyx Inc NASDAQ:ARDX	Biotechnology	41.14%
Xiangxue Pharmaceutical SHE:300147	Biotechnology	0.05%

Annual Asset Resilience Ratio for Addex Therapeutics Ltd (2017–2024)

The table below shows the annual Asset Resilience Ratio data for Addex Therapeutics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.06%	CHF6.50K ≈ $8.21K	CHF10.67 Million ≈ $13.49 Million	-83.23pp
2023-12-31	83.29%	CHF3.87 Million ≈ $4.89 Million	CHF4.64 Million ≈ $5.87 Million	-0.75pp
2022-12-31	84.04%	CHF6.96 Million ≈ $8.80 Million	CHF8.28 Million ≈ $10.47 Million	-6.91pp
2021-12-31	90.95%	CHF20.50 Million ≈ $25.92 Million	CHF22.54 Million ≈ $28.50 Million	-2.00pp
2020-12-31	92.95%	CHF18.76 Million ≈ $23.72 Million	CHF20.18 Million ≈ $25.52 Million	+78.84pp
2019-12-31	14.11%	CHF4.66 Million ≈ $5.89 Million	CHF33.03 Million ≈ $41.76 Million	+14.09pp
2018-12-31	0.02%	CHF7.98K ≈ $10.09K	CHF42.21 Million ≈ $53.37 Million	-0.35pp
2017-12-31	0.37%	CHF11.29K ≈ $14.27K	CHF3.06 Million ≈ $3.87 Million	--

pp = percentage points

About Addex Therapeutics Ltd

SW:ADXN Switzerland Biotechnology

Market Cap

$9.27 Million

CHF7.33 Million CHF

Market Cap Rank

#27648 Global

#209 in Switzerland

Share Price

CHF0.05

Change (1 day)

-0.40%

52-Week Range

CHF0.04 - CHF0.07

All Time High

CHF3.90